# Model Evaluation and Baseline Interpretability — DepMap Expression & PRISM Response

## Objective

This notebook performs **baseline model evaluation** on the drug-specific regression datasets constructed in previous steps.

The purpose of this stage is **not performance optimization**, but to:

- Establish realistic baseline performance levels
- Quantify per-drug predictability from gene expression alone
- Compare linear and non-linear reference models
- Identify signal heterogeneity across drugs
- Validate that the modeling setup is statistically and structurally sound

This notebook represents the **first quantitative validation layer** of the pipeline.

---

## Input datasets

This notebook operates exclusively on processed and validated artifacts generated upstream.

| Dataset | Description |
|-------|-------------|
| `depmap_expression_matched.parquet` | Gene expression matrix aligned to PRISM-screened cell lines |
| `prism_auc_filtered.parquet` | Filtered PRISM AUC measurements |
| `selected_drugs.parquet` | Subset of 100 prioritized modeling drugs (Notebook 03) |

No new biological features are introduced at this stage.

---

## Modeling scope

To ensure fast iteration and clear diagnostics, evaluation is restricted to:

- **5 representative drugs** selected from the prioritized subset
- **Independent modeling per drug**
- **Single-task regression** (predict PRISM AUC)

Each drug is treated as an independent learning problem:

> expression profile → continuous AUC response

This design explicitly avoids multi-drug pooling at this stage to preserve interpretability and diagnose drug-specific behavior.

---

## Feature construction

For each drug:

- One expression vector per cell line is used
- Expression data is **collapsed to one vector per `depmap_id`**
- Only **numeric gene expression features** are retained
- No feature selection or dimensionality reduction is applied

Final feature dimensionality:

- **~19,200 gene expression features**
- **~460–470 samples per drug**

This intentionally high-dimensional setup reflects the raw learning challenge.

---

## Train / test split strategy

Each drug-specific dataset is split using a fixed, reproducible strategy:

- **80% training**
- **20% test**
- Stratification is not applied (continuous target)
- Fixed random seed for reproducibility

Sample counts per drug are verified explicitly to prevent leakage or misalignment.

---

## Baseline models evaluated

Three complementary baseline regression models are trained and evaluated for each drug:

### Linear models
- **Ridge Regression**
- **ElasticNet Regression**

These models test:
- Linear signal presence
- Global regularized effects
- Stability in high-dimensional settings

### Non-linear model
- **Random Forest Regressor** (constrained configuration)

This model tests:
- Presence of non-linear structure
- Interaction-driven signal
- Robustness to noisy features

No hyperparameter optimization is performed at this stage.

---

## Evaluation metrics

Each model is evaluated on the **held-out test set** using:

| Metric | Interpretation |
|------|---------------|
| **R²** | Variance explained relative to baseline |
| **RMSE** | Absolute prediction error |
| **Spearman correlation** | Rank-based monotonic association |

Spearman correlation is included to capture **relative sensitivity ordering**, even when absolute prediction is weak.

---

## Baseline performance summary

Across the five evaluated drugs:

- **R² values are near zero or negative** for most models
- **RMSE values are consistent across models**
- **Spearman correlations vary substantially across drugs**

Key observations:

- Linear models rarely capture meaningful signal
- Random Forest occasionally shows improved rank correlation
- Predictability is **highly drug-dependent**
- Some drugs exhibit modest monotonic signal despite poor absolute fit

This confirms that:

- The task is **non-trivial**
- Signal is **weak-to-moderate** and heterogeneous
- Baseline performance is consistent with expectations for transcriptomics-only prediction

---

## Interpretation of baseline results

These results should **not** be interpreted as failure.

Instead, they establish:

- A realistic lower bound for performance
- A reference point for future modeling improvements
- Evidence that naive linear modeling is insufficient
- Indications that non-linear structure may exist for some drugs

Critically, the pipeline:

- Executes end-to-end without leakage
- Produces stable, interpretable diagnostics
- Preserves biological plausibility

---

## Outputs

This notebook produces:

| Artifact | Description |
|-------|-------------|
| Model performance table | Per-drug, per-model evaluation metrics |
| Console diagnostics | Explicit sample counts and sanity checks |

No files are persisted to disk at this stage.

---

## Conclusions

This notebook completes the **baseline evaluation layer** of the pipeline.

Key outcomes:

- End-to-end modeling workflow is validated
- Baseline performance is quantified honestly
- Drug-specific heterogeneity is evident
- Linear models provide weak baselines
- Non-linear models show selective promise

These results justify proceeding to:

- Feature attribution analysis
- Model diagnostics and error structure inspection
- Dimensionality reduction or representation learning
- Drug-specific modeling strategies

---

## Notes

This notebook deliberately avoids:

- Hyperparameter tuning
- Feature engineering
- Model selection
- Cross-drug pooling

Its role is strictly **diagnostic and foundational**, ensuring that all downstream modeling decisions are grounded in validated baseline behavior.

All subsequent notebooks assume:

- The regression task defined here
- The baseline performance ranges observed
- The per-drug modeling paradigm established
